Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMU-838 drug-drug interaction pharmacokinetic study with gemfibrozil and rifampicin
NL-OMON59991Phase 1Completed
- Sponsor
- Immunic Therapeutics
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vidofludimus calcium in multiple sclerosis (MS) (2 arms), sponsored by Immunic Therapeutics. Started Aug 2025; status: completed.
02
Drugs
vidofludimus calcium
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON59991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59991.